Biomarkers

Lines of research

Search for peripheral biomarkers in biological fluids such as blood, cerebrospinal fluid (CSF) and saliva using ultra-sensitivity technology, including:

• SIMOA (Single Molecule Array): Enables the detection of biomarkers at extremely low concentrations with high precision, ideal for early diagnosis of neurodegenerative diseases.
• Fujirebio: Specialises in automated immunoassays for the measurement of key biomarkers used in the diagnosis of Alzheimer's disease.
• Olink: We have data from our biological samples obtained using this high sensitivity and specificity proteomics technology that allows the simultaneous detection of multiple biomarkers in biological samples with minimal volumes. Designed to analyse key proteins involved in processes such as neuroinflammation, synaptic dysfunction and protein aggregation, essential factors in diseases such as Alzheimer's, Parkinson's and ALS, we have data on around 2,900 proteins. Thanks to its approach based on Proximity Extension Assay (PEA) technology, Olink offers accurate and reproducible quantification, facilitating the identification of new therapeutic targets and the search for biomarkers for the diagnosis and monitoring of neurodegenerative diseases. These technologies stand out for their ability to improve sensitivity and specificity in the detection of biomarkers, facilitating earlier and more accessible diagnosis for various neurodegenerative pathologies.

*RT Quic (Real-Time Quaking-Induced Conversion): is an innovative tool used to detect the presence of misfolded proteins, such as alpha-synuclein and tau, associated with neurodegenerative diseases. Its non-invasive nature, using biological fluids such as CSF or blood, and its ability to accurately identify pathological changes make it a promising tool for research and clinical diagnosis.

*Extracellular particles (EVs): play a crucial role in intercellular communication and have emerged as biomarkers and potential mediators in neurodegenerative diseases. These nanometric structures, released by various cell types, transport proteins, lipids and genetic material, modulating neuronal homeostasis and inflammatory response. In pathologies such as Alzheimer's disease, Parkinson's disease and ALS, EVs may facilitate the propagation of misfolded proteins, contributing to neurodegeneration. They also possess neuroprotective properties by removing toxic aggregates and regulating the immune response. Their study opens up new opportunities for the development of innovative diagnostic and therapeutic strategies in neurology.

*Searching for genetic susceptibility factors to understand predisposition to various diseases, including neurodegenerative diseases. These findings not only improve knowledge of the underlying molecular mechanisms, but may also contribute to the development of early diagnostic tools and personalised medicine strategies, allowing more effective interventions tailored to the individual genetics of each patient, based on precision medicine.

*DNA and biological samples biobank, a key infrastructure for research in neurosciences and other biomedical areas. Our biobank has:

• DNA biobank: Collection of high quality samples for genetic and biomarker studies.
• Biobank of biological samples: Includes blood, cerebrospinal fluid (CSF), saliva, tears and hair, allowing a multidimensional approach to disease research.

Our biobank is a key resource for advancing our understanding of the molecular mechanisms of disease and the development of new diagnostic and therapeutic strategies.

*Research platform for external groups: we offer access to our samples and data under strict ethical and quality protocols, facilitating collaboration with other national and international research groups.

* External service for the use of SIMOA, Fujirebio and Real Time - PCR (coming soon): We offer a specialised service for research groups and companies that require the use of advanced technologies in biomarkers and molecular analysis. We have state-of-the-art platforms such as SIMOA (Single Molecule Array), which allows the ultra-sensitive detection of proteins in biological fluids; Fujirebio, recognised for its high precision in the analysis of neurodegenerative biomarkers through automated assays; and Real Time-PCR, ideal for the quantification of nucleic acids in gene expression studies and molecular diagnostics. Our team offers technical support and advice to optimise the use of these technologies in biomedical research projects.